DNA Nanomaterials‐Based Platforms for Cancer Immunotherapy

The past few decades have witnessed the evolving paradigm for cancer therapy from nonspecific cytotoxic agents to selective, mechanism‐based therapeutics, especially immunotherapy. In particular, the integration of nanomaterials with immunotherapy is proven to improve the therapeutic outcome and min...

Full description

Saved in:
Bibliographic Details
Published in:Small methods 2023-05, Vol.7 (5), p.e2201518-n/a
Main Authors: Tian, Run, Shang, Yingxu, Wang, Yiming, Jiang, Qiao, Ding, Baoquan
Format: Article
Language:English
Subjects:
Antineoplastic Agents
cancer immunotherapy
DNA nanomaterials
Humans
immune cell engineering
immunogenic cell death
Immunotherapy
Nanomedicine
Nanostructures - therapeutic use
nanovaccines
Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The past few decades have witnessed the evolving paradigm for cancer therapy from nonspecific cytotoxic agents to selective, mechanism‐based therapeutics, especially immunotherapy. In particular, the integration of nanomaterials with immunotherapy is proven to improve the therapeutic outcome and minimize off‐target toxicity in the treatment. As a novel nanomaterial, DNA‐based self‐assemblies featuring uniform geometries, feasible modifications, programmability, surface addressability, versatility, and intrinsic biocompatibility, are extensively exploited for innovative and effective cancer immunotherapy. In this review, the successful employment of DNA nanoplatforms for cancer immunotherapy, including the delivery of immunogenic cell death inducers, adjuvants and vaccines, immune checkpoint blockers as well as the application in immune cell engineering and adoptive cell therapy is summarized. The remaining challenges and future perspectives regarding the pharmacokinetics/pharmacodynamics, in vivo fate and immunogenicity of DNA materials, and the design of intelligent DNA nanomedicine for individualized cancer immunotherapy are also discussed. Immunotherapy is an emerging and promising method for cancer treatment. As a novel nanomaterial, DNA materials‐based platforms are extensively employed to improve cancer immunotherapy including transporting immunogenic cell death inducers, immunostimulatory adjuvants and antigens, immune checkpoint blockers, and targeting moieties as well as engineering immune cells for adoptive therapy.
ISSN:2366-9608
2366-9608
DOI:10.1002/smtd.202201518